Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?

Saved in:
Bibliographic Details
Published in:Leukemia 2023-12, Vol.37 (12), p.2517-2519
Main Authors: Bouchla, Anthi, Papageorgiou, Sotirios G., Symeonidis, Argyris, Sakellari, Ioanna, Zikos, Panagiotis, Thomopoulos, Thomas P., Hatzimichael, Eleftheria, Galanopoulos, Athanasios, Vyniou, Nora-Athina, Kotsianidis, Ioannis, Pappa, Vasiliki
Format: Article
Language:English
Subjects:
692/499
692/699/1541/1990/1673
Antimetabolites, Antineoplastic - therapeutic use
Azacitidine - therapeutic use
Blood platelets
Cancer Research
Clinical trials
Critical Care Medicine
Hematology
Hospitals
Humans
Intensive
Internal Medicine
Letter
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Medical prognosis
Medicine
Medicine & Public Health
Myelodysplastic Syndromes - drug therapy
Oncology
Patients
Remission Induction
Stem cell transplantation
Survival analysis
Treatment Outcome
Working groups
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0887-6924
1476-5551
1476-5551
DOI:10.1038/s41375-023-02051-3